In vitro Assays on Patient-Relevant Models of Cell Lines
Our resources include an extensive panel of hematologic cancer cell lines, featuring commercial models, a unique proprietary collection of multiple myeloma cell lines, and acquired-resistant variants. These models reflect the molecular and clinical heterogeneity observed in patients, including subclones, mutations, and diverse resistance profiles.
Ex vivo assays on primary patients samples
Diag2Tec has privileged access to a large collection of patient-derived primary samples with various hematologic malignancies, including newly diagnosed and relapsed cases, available for ex vivo assay. These samples are from different origins (bone marrow, blood, tissues), and preserve the biological complexity and heterogeneity observed in patients, providing a unique opportunity to assess drug responses in clinically meaningful contexts.
Ex-vivo assays on normal Plasma Cell Differentiation Model
Diag2Tec provides advanced, human-relevant platform to investigate normal B-cell to plasma cell differentiation, enabling the evaluation of therapeutic strategies in multiple myeloma and autoimmune diseases.
Ex-vivo assays for Immuno-Oncology
Given the increasingly important role of immunotherapy agents in the treatment of haematological cancers, Diag2Tec developed services to evaluate the efficacy, mechanisms of action, and resistance of immune-based therapies in our hematologic malignancies models (cell lines, primary samples and plasma cell differentiation model).